ResearcherNantong UniversityNo recent work listed
Chunhua Wan
Matched on ORCID iD 0000-0003-2896-0989; OpenAlex author ID A5008161715. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2015: 2 papers · 2016: 3 papers · 2017: 1 paper
Papers 6
- CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Co-author DOI 10.18632/oncotarget.14037↗
- β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Co-author DOI 10.1016/j.canlet.2016.01.026↗
- Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.humpath.2016.07.015↗
- RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. Last author DOI 10.1016/j.yexmp.2016.08.001↗
- NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11010-015-2535-7↗
- High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1007/s13277-015-3625-6↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guoxiong Zhou · 5 shared papers, 2015–2016 · strength 0.25
- Paper RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. DOI 10.1016/j.yexmp.2016.08.001↗
- Paper Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcin… DOI 10.1016/j.humpath.2016.07.015↗
- Paper β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP… DOI 10.1016/j.canlet.2016.01.026↗
- Ying Xiao · 3 shared papers, 2016 · strength 0.16
- Paper RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. DOI 10.1016/j.yexmp.2016.08.001↗
- Paper Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcin… DOI 10.1016/j.humpath.2016.07.015↗
- Paper β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP… DOI 10.1016/j.canlet.2016.01.026↗
- Xiaohong Li · 2 shared papers, 2016 · strength 0.11
- Mingbing Xiao · 2 shared papers, 2016 · strength 0.11
- Gong Chen · 2 shared papers, 2015–2016 · strength 0.10
- Paper β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP… DOI 10.1016/j.canlet.2016.01.026↗
- Paper High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). DOI 10.1007/s13277-015-3625-6↗
- Xiaorong Liu · 2 shared papers, 2015 · strength 0.09
- Paper High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). DOI 10.1007/s13277-015-3625-6↗
- Paper NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcino… DOI 10.1007/s11010-015-2535-7↗
- Ji Li · 2 shared papers, 2015 · strength 0.09
- Paper High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). DOI 10.1007/s13277-015-3625-6↗
- Paper NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcino… DOI 10.1007/s11010-015-2535-7↗
- Sujie Ni · 1 shared paper, 2017 · strength 0.06
- Zhixian He · 1 shared paper, 2017 · strength 0.06
- Wei Ting Wang · 1 shared paper, 2017 · strength 0.06
- Xiaolin Zhu · 1 shared paper, 2017 · strength 0.06
- Jiaqi He · 1 shared paper, 2017 · strength 0.06
- Chongyi Jiang · 1 shared paper, 2017 · strength 0.06
- Aiguo Shen · 1 shared paper, 2016 · strength 0.05
- Wei Cao · 1 shared paper, 2016 · strength 0.05
- Xiaoling Ding · 1 shared paper, 2016 · strength 0.05
- Haifeng Zhang · 1 shared paper, 2015 · strength 0.05
- Liang Wang · 1 shared paper, 2015 · strength 0.04
- Yixin Zhang · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.